BioNexus Gene Lab

BioNexus Gene Lab EPS Growth

The EPS Growth of BioNexus Gene Lab (BGLC) as of Oct 30, 2026 is -38.80 %. In the previous year, EPS Growth was 40.22 % — a change of -196.47% (lower).

EPS Growth

-38.80 %

YoY

-196.47%

Last updated:

EPS Growth of BioNexus Gene Lab is 2025 -38.80 % . EPS Growth of BioNexus Gene Lab was 2024 40.22 % . It decreases by -196.47% lower compared to the previous year.

The BioNexus Gene Lab EPS Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS Growth
Date
EPS Growth
Jan 1, 2018
118.02 USD
Jan 1, 2019
-662.86 USD
Jan 1, 2020
548.85 USD
Jan 1, 2021
-99.65 USD
Jan 1, 2022
-660.18 USD
Jan 1, 2023
-5,951.53 USD
Jan 1, 2024
40.22 USD
Jan 1, 2025
-38.80 USD
The BioNexus Gene Lab EPS Growth history
YEAREPS GrowthYoY
-38.80 %-196.47%
40.22 %-100.68%
-5,951.53 %+801.51%
-660.18 %+562.47%
-99.65 %-118.16%
548.85 %-182.80%
-662.86 %-661.65%
118.02 %-100.15%
-80,569.33 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

BioNexus Gene Lab Stock analysis

What does BioNexus Gene Lab do? BioNexus Gene Lab Corp. develops and markets non-invasive blood tests for early disease detection, analyzing RNA changes to assess risks for over 11 diseases. The company’s subsidiary, Bionexus Gene Lab Sdn. Bdh., supports these operations. Products are sold to healthcare providers and diagnostic centers seeking advanced, non-invasive testing solutions. The firm targets medical professionals and institutions focused on personalized health management through functional genomics applications. The company generates revenue through the sale of its RNA-based blood tests, which are marketed as tools for early disease risk assessment. Healthcare institutions and diagnostic service providers purchase these tests to enhance their diagnostic capabilities. The focus on non-invasive methods aligns with growing demand for patient-friendly diagnostic technologies in the molecular diagnostics sector. BioNexus Gene Lab Corp. operates with a small team of 5 full-time employees, emphasizing efficiency in product development and marketing. The subsidiary Bionexus Gene Lab Sdn. Bdh. facilitates local operations, though specific market segments are not detailed beyond healthcare providers and diagnostic centers. Revenue streams are derived solely from test sales, with no mention of additional services or partnerships. BioNexus Gene Lab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioNexus Gene Lab stock

EPS Growth of BioNexus Gene Lab is -38.80 % in 2025.

On Eulerpool you can find the complete historical development of EPS Growth BioNexus Gene Lab since 2006 – with annual values, charts, and detailed analysis.

EPS growth measures the percentage change in earnings per share. It accounts for both profit changes and share count changes.

To evaluate EPS Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EPS Growth.

EPS Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EPS Growth's BioNexus Gene Lab historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Growth — BioNexus Gene Lab

Revenue GrowthRevenue CAGR 3YRevenue CAGR 5YRevenue CAGR 10YEarnings GrowthEPS GrowthEBIT GrowthEBIT CAGR 3YEBIT CAGR 5YEBIT CAGR 10YDividend GrowthFCF GrowthBook Value GrowthEarnings CAGR 3YEarnings CAGR 5YEarnings CAGR 10YEPS CAGR 3YEPS CAGR 5YEBITDA Growth YoYEBITDA CAGR 3YEBITDA CAGR 5YGross Profit GrowthOCF Growth YoYEmployee GrowthDividend CAGR 3YDividend CAGR 5YDividend CAGR 10YAsset GrowthEquity GrowthDebt GrowthCapEx GrowthFCF CAGR 3YFCF CAGR 5YMarket Cap GrowthShare Count Growth

All Key Metrics — BioNexus Gene Lab